Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16564| Title: | Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimer's disease | Austin Authors: | Sabbagh, Marwan N;Schäuble, Barbara;Anand, Keshav;Richards, Danielle;Murayama, Shigeo;Akatsu, Hiroyasu;Takao, Masaki;Rowe, Christopher C ;Masters, Colin L ;Barthel, Henryk;Gertz, Hermann-Josef;Peters, Oliver;Rasgon, Natalie;Jovalekic, Aleksandar;Sabri, Osama;Schulz-Schaeffer, Walter;Seibyl, John | Affiliation: | Alzheimer’s and Memory Disorders Division, Barrow Neurological Institute, Phoenix, AZ, USA Formerly Piramal Imaging GmbH, Berlin, Germany Banner Sun Health Research Institute, Sun City, AZ, USA Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan Fukushimura Hospital, Toyohashi, Japan Departments of Community-based Medicine and Neurology, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Aichi, Japan Mihara Memorial Hospital, Isesaki, Japan Austin Health, University of Melbourne, Heidelberg, Victoria, Australia The Florey Institute, The University of Melbourne, Australia Department of Nuclear Medicine, Leipzig University, Leipzig, Germany Department of Psychiatry, Leipzig University, Leipzig, Germany Department of Psychiatry and Psychotherapy, Charité Berlin, Berlin, Germany Department of Psychiatry, Stanford School of Medicine, Stanford, USA Piramal Imaging GmbH, Berlin, Germany Georg-August University Göttingen, Göttingen, Germany Molecular Neuroimaging, New Haven, CT, USA |
Issue Date: | 24-Jan-2017 | Publication information: | Journal of Alzheimer's Disease 2017; 56(2): 441-446 | Abstract: | Of 57 individuals diagnosed with Alzheimer’s disease (AD) in a phase III study, 13 (23%) had amyloid-β (Aβ) levels on postmortem histopathology that did not explain the dementia. Based on postmortem histopathology, a wide range of different non-AD conditions was identified, including frontotemporal dementia, hippocampal sclerosis, and dementia with Lewy bodies. Of the histopathologically Aβ negative scored cases ante-mortem Florbetaben PET scans were classified as negative for Aβ in 11 patients based on visual analysis and in all 12 quantifiable cases based on composite standardized uptake value ratios. Thus, florbetaben PET can assist physicians in the differential diagnosis of neurodegenerative disorders by reliably excluding Aβ pathology. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16564 | DOI: | 10.3233/JAD-160821 | ORCID: | 0000-0003-3910-2453 | Journal: | Journal of Alzheimer's Disease | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/27983552 | Type: | Journal Article | Subjects: | Alzheimer’s disease Florbetaben PET Histopathology |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.